EVI1 protein interaction dynamics: Targetable for therapeutic intervention?

Exp Hematol. 2022 Mar:107:1-8. doi: 10.1016/j.exphem.2021.12.398. Epub 2021 Dec 24.

Abstract

High expression of the transcriptional regulator EVI1 encoded at the MECOM locus at 3q26 is one of the most aggressive oncogenic drivers in acute myeloid leukemia (AML) and carries a very poor prognosis. How EVI1 confers leukemic transformation and chemotherapy resistance in AML is subject to important ongoing clinical and experimental studies. Recent discoveries have revealed critical details on genetic mechanisms of the activation of EVI1 overexpression and downstream events of aberrantly high EVI1 expression. Here we review and discuss aspects concerning the protein interactions of EVI1 and the related proteins MDS-EVI1 and ΔEVI1 from the perspective of their potential for therapeutic intervention.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • DNA-Binding Proteins* / metabolism
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / metabolism
  • MDS1 and EVI1 Complex Locus Protein / genetics
  • Prognosis
  • Transcription Factors / metabolism

Substances

  • DNA-Binding Proteins
  • MDS1 and EVI1 Complex Locus Protein
  • Transcription Factors